Co-Diagnostics, Inc.

CODX

Revenue declined 84.1% to $622.5K as prior-year grant recognition ended, while operating loss widened 25.2% to -$50.2M from heavier impairments despite gross margin expansion to 64.3%.

OTC

Healthcare

Medical - Devices

Salt Lake City, UT, US132 employeesco-dx.com

$1.55

-0.07(-4.3%)

52W $2.11 – $248.31

AI-generated

Revenue declined 84.1% to $622.5K as prior-year grant recognition ended, while operating loss widened 25.2% to -$50.2M from heavier impairments despite gross margin expansion to 64.3%.

Revenue breakdown: Grant (73.8%), Product (26.2%).

$2MMkt Cap

—Rev TTM

—NI TTM

Latest Earnings

10-K

FY FY2025Mar 30, 2026

Revenue declined 84.1% to $622.5K as prior-year grant recognition ended, while operating loss widened 25.2% to -$50.2M from heavier impairments despite gross margin expansion to 64.3%.

Read full analysis View SEC Filing

What Changed Recently

Financial Results

Mar 30, 2026

or Exhibit 99.1 shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 19

View filing →

Financial Results

Mar 9, 2026

by reference. Item 8.01. Other Events. Nasdaq Matters On March 9, 2026, Co-Diagnostics, Inc. (the “Company”) was formally notified by The Nasdaq Stock Market LL

View filing →

Delisting

Jan 12, 2026

. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On January 7, 2026, Co-Diagnostics, Inc. (the “Company”) r

View filing →

View all recent events →

Fundamentals